| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1,8-Cineole — 1,8-cineole, also called eucalyptol, is a volatile bicyclic monoterpene ether and major active constituent of eucalyptus oil and several other aromatic plant oils (other plants such as oregano (Origanum spec.), thyme (Thymus spec.), guava (Psidium pohlianum) or sage (Salvia spec.)). Eucalyptus oil used for medicinal applications should contain at least 70% of 1,8-Cineol. It is best classified as a small-molecule phytochemical / essential-oil monoterpenoid rather than as a botanical extract. Its main established human-use identity is respiratory anti-inflammatory / mucolytic support, while its oncology relevance is preclinical and concentration-limited. Primary mechanisms (ranked):
Bioavailability / PK relevance: 1,8-cineole is orally and inhalationally absorbed and undergoes rapid systemic distribution, with CYP3A-mediated oxidation as an important metabolic route. Enteric-coated oral preparations can deliver measurable tissue exposure in airway/nasal tissues, but oncology-relevant systemic concentrations are not established. In-vitro vs systemic exposure relevance: Many anticancer studies use millimolar-range in-vitro concentrations or concentrated essential-oil fractions, which likely exceed routine achievable systemic exposure from conventional oral or inhaled use. Direct cancer-cell effects should therefore be marked as exposure-constrained unless a delivery formulation is specified. Clinical evidence status: Preclinical oncology only. There is cell-line and animal/xenograft evidence for anticancer activity, but no established cancer-directed clinical efficacy. Human clinical deployment is mainly respiratory/supportive use of eucalyptus oil or purified 1,8-cineole preparations, not antineoplastic therapy. 1,8-Cineole Cancer Mechanism Summary
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr |
| Source: |
| Type: |
| The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues. Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance Factors that affect selectivity: 1. Ability of Cancer cells to preferentially absorb a product/drug -EPR-enhanced permeability and retention of cancer cells -nanoparticle formations/carriers may target cancer cells over normal cells -Liposomal formations. Also negatively/positively charged affects absorbtion 2. Product/drug effect may be different for normal vs cancer cells - hypoxia - transition metal content levels (iron/copper) change probability of fenton reaction. - pH levels - antiOxidant levels and defense levels 3. Bio-availability |
| 6476- | 1,8-Cin, | Specific induction of apoptosis by 1,8-cineole in two human leukemia cell lines, but not a in human stomach cancer cell line |
| - | in-vitro, | AML, | NA |
| 6467- | 1,8-Cin, | Evaluation of in vitro anticancer activity of 1,8-Cineole-containing n-hexane extract of Callistemon citrinus (Curtis) Skeels plant and its apoptotic potential |
| - | in-vitro, | Melanoma, | A431 | - | in-vitro, | OS, | MG63 | - | in-vitro, | Nor, | HaCaT |
| 6464- | LIN, | 1,8-Cin, | Anti-cancer mechanisms of linalool and 1,8-cineole in non-small cell lung cancer A549 cells |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | Nor, | WI38 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:409 Target#:1110 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid